Search details
1.
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.
J Pharmacol Exp Ther
; 351(2): 403-12, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25204339
2.
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Hepatology
; 57(6): 2143-54, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23359516
3.
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Hepatology
; 57(6): 2155-63, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-23504636
4.
Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
Antivir Ther
; 11(3): 371-6, 2006.
Article
in English
| MEDLINE | ID: mdl-16759054
5.
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Hepatology
; 41(4): 832-5, 2005 Apr.
Article
in English
| MEDLINE | ID: mdl-15732092
6.
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.
Gastroenterology
; 127(5): 1347-55, 2004 Nov.
Article
in English
| MEDLINE | ID: mdl-15521004
Results
1 -
6
de 6
1
Next >
>>